Prostate cancer is the most common non-cutaneous malignancy for men.
The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.
Written by:
De Placido S, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, Izzo M, Policastro T, Di Lorenzo G. Are you the author?
Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Napoli 80140, Italy.
Reference: World J Clin Cases. 2014 Jun 16;2(6):228-31.
doi: 10.12998/wjcc.v2.i6.228
PubMed Abstract
PMID: 24945013
UroToday.com mCRPC Treatment Section
